MedTrace Logo

Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)

NCT01109810 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 496

Last updated 2022-06-22

No results posted yet for this study

Summary

The IDEaL registry is a cooperative, observational registry focused on immunoglobulin use in the U.S. The registry is a deliberate and purposeful assembly of clinical and humanistic knowledge that is intended to act as a longitudinal database, tracking outcomes of routine clinical practice.

The central goal of the registry is to provide a mechanism that allows for a better understanding of how immunoglobulin therapy is being used in a real-world clinical setting. The data gathered will help the industry gain a better understanding surrounding the therapeutic value of immunoglobulin therapy and subsequently improve practices, reduce medical costs, and ultimately improve the clinical outcomes for the patients receiving immunoglobulin therapy

Conditions

  • IVIg or SCIg Therapy in the Home or at Alternate Site

Sponsors & Collaborators

  • Coram Clinical Trials

    lead OTHER

Principal Investigators

  • Luqman Seidu, MD · Omni Allergy, Immunology, and Asthma

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-08
Primary Completion
2022-06-10
Completion
2022-06-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01109810 on ClinicalTrials.gov